Forgot Password

Please enter your email below.*
To create your new password, please enter your email address below.
We will send an email with instructions to reset your password.
*It must be the same email you used to register for your account


Venous thromboembolism (VTE) events manifest as deep vein thrombosis and pulmonary embolisms. These events can often occur in surgical patients within 6 weeks post discharge. The vitamin K agonist warfarin has historically been used for VTE treatment and prophylaxis, but is associated with numerous challenges such as dosage adjustments due to variable dose response. However, in the past decade direct oral anticoagulants (DOACs) have emerged with a role in VTE treatment and prophylaxis. DOACs have improved dosing and limited interactions, both of which are important considerations for pharmacists involved in transitions of care for patients at high risk for VTE. Pharmacists practicing in the health-system setting have important roles in establishing protocols and promoting the utilization of DOACs for VTE prophylaxis in high-risk patients to prevent serious post-discharge complications and decrease associated financial burden. This VTE Curriculum series will equip pharmacists to identify patients at high risk for VTE through included patient case activities. Pharmacists who complete all activities in the Curriculum will receive a Certificate of Completion, demonstrating their dedication to improving patient outcomes with the use of DOACs in VTE.

CE Activity Curriculum

Additional Videos


Latest News

BMI, LDL Cholesterol Are Important Metrics in Assessing COVID-19 Risk

Learn More >

Week in Review: Study Shows Substance Use Disorders Possibly Linked to COVID-19

Learn More >

FDA Approves New Treatment for Transthyretin Amyloid Cardiomyopathy

Learn More >

Trending News Today: Young Women Have Low Awareness of Cardiovascular Risks

Learn More >

Study: Daily Aspirin Does Not Reduce Risk of Major Cardiovascular Events

Learn More >

ASCEND Trial: Aspirin Prevents Serious Vascular Events in Diabetes

Learn More >

Study: Daily Aspirin Did Not Reduce Risk of First Heart Attack, Stroke

Learn More >

Individuals with HIV Twice as Likely to Develop Heart Disease

Learn More >


This resource center is supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.

Personalize the information you receive by selecting targeted content and special offers.